Light chain amyloidosis 2012: A new era

British Journal of Haematology

Volumn 160, Issue 5, 2013, Pages 582-598

  Gatt, Moshe E ^a   Palladini, Giovanni ^b,c  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

Amyloidosis; Novel agents; Prognosis; Therapy

Indexed keywords

1 [6 [2 CARBOXYPYRROLIDIN 1 YL] 6 OXO HEXANOYL]PYRROLIDINE 2 CARBOXYLIC ACID; ALKYLATING AGENT; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMYLOID P COMPONENT; AMYLOID PROTEIN; BENDAMUSTINE; BORTEZOMIB; BRAIN NATRIURETIC PEPTIDE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; IMMUNOMODULATING AGENT; IXAZOMIB CITRATE; LENALIDOMIDE; MELPHALAN; POMALIDOMIDE; PREDNISONE; PROTEASOME INHIBITOR; PROTEIN INHIBITOR; RITUXIMAB; THALIDOMIDE; TROPONIN T; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; AMYLOIDOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW TOXICITY; BRADYCARDIA; CARDIOTOXICITY; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); CONSTIPATION; CYTOPENIA; CYTOTOXICITY; DISEASE ASSOCIATION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FATIGUE; FLUID RETENTION; HEART AMYLOIDOSIS; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HIGH RISK PATIENT; HUMAN; HYPOTENSION; KIDNEY DYSFUNCTION; LONG TERM SURVIVAL; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; ORGAN TRANSPLANTATION; OVERALL SURVIVAL; PATIENT SELECTION; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RISK ASSESSMENT; SALVAGE THERAPY; SEDATION; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

ALKYLATING AGENTS; AMYLOID; AMYLOIDOSIS; BIOLOGICAL MARKERS; BORONIC ACIDS; CARDIOMYOPATHIES; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DEXAMETHASONE; FORECASTING; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOLOGIC FACTORS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; PYRAZINES; RISK; SEVERITY OF ILLNESS INDEX; STEM CELL TRANSPLANTATION; TROPONIN C; TROPONIN T;

EID: 84873993447     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12191     Document Type: Review

References (152)

1. Afghahi, A., Witteles, W., Witteles, R., Liedtke, M., Lafayette, R., Arai, S. & Schrier, S.L. (2011) A pilot study of melphalan, lenalidomide and dexamethasone in AL amyloidosis: interim results. Blood (ASH Annual Meeting Abstracts), 116, 1946.
2. Anesi, E., Palladini, G., Perfetti, V., Arbustini, E., Obici, L. & Merlini, G. (2001) Therapeutic advances demand accurate typing of amyloid deposits. American Journal of Medicine, 111, 243-244.
3. Arbustini, E., Verga, L., Concardi, M., Palladini, G., Obici, L. & Merlini, G. (2002) Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis. Amyloid, 9, 108-114.
4. Auner, H., Mazzarella, L., Cook, L., Szydlo, R., Saltarelli, F., Pavlu, J., Bua, M., Giles, C., Apperley, J. & Rahemtulla, A. (2010) High rate of stem cell mobilization failure after thalidomide and oral cyclophosphamide induction therapy for multiple myeloma. Bone Marrow Transplantation, 46, 364-367.
5. Bansal, T., Garg, A., Snowden, J.A. & McKane, W. (2012) Defining the role of renal transplantation in the modern management of multiple myeloma and other plasma cell dyscrasias. Nephron. Clinical Practice, 120, c228-c235.
6. Bianchi, G., Oliva, L., Cascio, P., Pengo, N., Fontana, F., Cerruti, F., Orsi, A., Pasqualetto, E., Mezghrani, A., Calbi, V., Palladini, G., Giuliani, N., Anderson, K., Sitia, R. & Cenci, S. (2009) The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood, 113, 3040-3049.
7. Bodin, K., Ellmerich, S., Kahan, M.C., Tennent, G.A., Loesch, A., Gilbertson, J.A., Hutchinson, W.L., Mangione, P.P., Gallimore, J.R., Millar, D.J., Minogue, S., Dhillon, A.P., Taylor, G.W., Bradwell, A.R., Petrie, A., Gillmore, J.D., Bellotti, V., Botto, M., Hawkin, P.N. & Pepys, M.B. (2010) Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature, 468, 93-97.
8. Brambilla, F., Lavatelli, F., Di Silvestre, D., Valentini, V., Rossi, R., Palladini, G., Obici, L., Verga, L., Mauri, P. & Merlini, G. (2012) Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood, 119, 1844-1847.
9. Cibeira, M.T., Sanchorawala, V., Seldin, D.C., Quillen, K., Berk, J.L., Dember, L.M., Segal, A., Ruberg, F., Meier-Ewert, H., Andrea, N.T., Sloan, J.M., Finn, K.T., Doros, G., Blade, J. & Skinner, M. (2011) Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood, 118, 4346-4352.
10. Cocks, K., Gibbs, S., Sattianayagam, P., Lane, T., Lachmann, H., Schey, S., Cavenagh, J., Oakervee, H., Morgan, G., Mehta, A., Bourne, S., Skinner, E., Booth, G., Hawkins, P. & Wechalekar, A. (2009) Cyclophosphamide, thalidomide and dexamethasone (CTD) versus melphalan plus dexamethasone (MD) for newly-diagnosed systemic AL amyloidosis - results from the UK amyloidosis treatment trial. ASH Annual Meeting Abstracts, Blood, 114, 1120.
11. Cohen, A., Zhou, P., Chou, J., Teruya-Feldstein, J., Reich, L., Hassoun, H., Levine, B., Filippa, D., Riedel, E., Kewalramani, T., Stubblefield, M., Fleisher, M., Nimer, S. & Comenzo, R. (2007) Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial. British Journal of Haematology, 139, 224-233.
12. Comenzo, R., Vosburgh, E., Falk, R., Sanchorawala, V., Reisinger, J., Dubrey, S., Dember, L., Berk, J., Akpek, G., LaValley, M., O'hara, C., Arkin, C., Wright, D. & Skinner, M. (1998) Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood, 91, 3662-3670.
13. Comenzo, R., Zhou, P., Fleisher, M., Clark, B. & Teruya-Feldstein, J. (2006) Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins. Blood, 107, 3489-3491.
14. Comenzo, R.L., Hegenbart, U., Sanchorawala, W., Merlini, G., Palladini, G., Bladé, J., Fermand, J.P., Hassoun, H., Heffner, L., Vescio, R.A., Liu, K., Enny, C., Esseltine, D.L., van de Velde, H., Cakana, A. & Reece, D.E. (2010) High rates of overall and complete haematologic response in a prospective phase 1/2 study of weekly and twice weekly bortezomib in relapsed AL amyloidosis. Amyloid, 17, 83-84.
15. Comenzo, R.L., Reece, D., Palladini, G., Seldin, D., Sanchorawala, V., Landau, H., Falk, R., Wells, K., Solomon, A., Wechalekar, A., Zonder, J., Dispenzieri, A., Gertz, M., Streicher, H., Skinner, M., Kyle, R.A. & Merlini, G. (2012) Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain (AL) amyloidosis. Leukemia, 26, 2317-2325.
16. Cordes, S., Dispenzieri, A., Lacy, M.Q., Hayman, S.R., Buadi, F.K., Dingli, D., Kumar, S.K., Hogan, W.J. & Gertz, M.A. (2012) Ten year survival following autologous stem cell transplantation for immunoglobulin light chain amyloidosis. XIIIth International Symposium on Amyloidosi, PC38. http://wencke4.housing.rug.nl/documenten/medici/Internationale_Conferenties/SY_Amyloidosis%202012/documents/ISAabstractbook2012.pdf.
17. Damaj, G., Malard, F., Hulin, C., Caillot, D., Garidi, R., Royer, B., Marit, G., Stoppa, A.M., Banos, A., Morineau, N., Moreau, P., Fitoussi, O. & Tiab, M. (2012) Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program. Leukaemia & Lymphoma, 53, 632-634.
18. Desikan, K.R., Dhodapkar, M.V., Hough, A., Waldron, T., Jagannath, S., Siegel, D., Barlogie, B. & Tricot, G. (1997) Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation. Leukaemia & Lymphoma, 27, 315-319.
19. Dey, B., Chung, S., Spitzer, T., Zheng, H., Macgillivray, T., Seldin, D., McAfee, S., Ballen, K., Attar, E., Wang, T., Shin, J., Newton-Cheh, C., Moore, S., Sanchorawala, V., Skinner, M., Madsen, J. & Semigran, M. (2010) Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure. Transplantation, 90, 905-911.
20. Dhodapkar, M., Jagannath, S., Vesole, D., Munshi, N., Naucke, S., Tricot, G. & Barlogie, B. (1997) Treatment of AL-amyloidosis with dexamethasone plus alpha interferon. Leukaemia & Lymphoma, 27, 351-356.
21. Dietrich, S., Schönland, S., Benner, A., Bochtler, T., Kristen, A., Beimler, J., Hund, E., Zorn, M., Goldschmidt, H., Ho, A. & Hegenbart, U. (2010) Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. Blood, 116, 522-528.
22. Dietrich, S., Hegenbart, U., Bochtler, T., Kristen, A.V., Goldschmidt, H., Ho, A.D. & Schönland, S. (2012) Revlimide-Dexamethasone in patients with relapsed light chain amyloidosis previous high dose chemotherapy does not impair response and revival. XIIIth International Symposium on Amyloidosis, PC55. http://wencke4.housing.rug.nl/documenten/medici/Internationale_Conferenties/SY_Amyloidosis%202012/documents/ISAabstractbook2012.pdf.
23. Dimopoulos, M.A., Richardson, P.G., Brandenburg, N., Yu, Z., Weber, D.M., Niesvizky, R. & Morgan, G.J. (2012) A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood, 119, 2764-2767.
24. Dispenzieri, A., Kyle, R., Gertz, M., Therneau, T., Miller, W., Chandrasekaran, K., McConnell, J., Burritt, M. & Jaffe, A. (2003a) Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet, 361, 1787-1789.
25. Dispenzieri, A., Lacy, M., Rajkumar, S., Geyer, S., Witzig, T., Fonseca, R., Lust, J., Greipp, P., Kyle, R. & Gertz, M. (2003b) Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid, 10, 257-261.
26. Dispenzieri, A., Gertz, M., Kyle, R., Lacy, M., Burritt, M., Therneau, T., Greipp, P., Witzig, T., Lust, J., Rajkumar, S., Fonseca, R., Zeldenrust, S., McGregor, C. & Jaffe, A. (2004a) Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. Journal of Clinical Oncology, 22, 3751-3757.
27. Dispenzieri, A., Gertz, M., Kyle, R., Lacy, M., Burritt, M., Therneau, T., McConnell, J., Litzow, M., Gastineau, D., Tefferi, A., Inwards, D., Micallef, I., Ansell, S., Porrata, L., Elliott, M., Hogan, W., Rajkumar, S., Fonseca, R., Greipp, P., Witzig, T., Lust, J., Zeldenrust, S., Snow, D., Hayman, S., McGregor, C. & Jaffe, A. (2004b) Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood, 104, 1881-1887.
28. Dispenzieri, A., Lacy, M., Zeldenrust, S., Hayman, S., Kumar, S., Geyer, S., Lust, J., Allred, J., Witzig, T., Rajkumar, S., Greipp, P., Russell, S., Kabat, B. & Gertz, M. (2007) The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood, 109, 465-470.
29. Dispenzieri, A., Dingli, D., Kumar, S., Rajkumar, S., Lacy, M., Hayman, S., Buadi, F., Zeldenrust, S., Leung, N., Detweiler-Short, K., Lust, J., Russell, S., Kyle, R. & Gertz, M. (2010) Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. American Journal of Hematology, 85, 757-759.
30. Dispenzieri, A., Buadi, F., Laumann, K., Laplant, B., Hayman, S.R., Kumar, S.K., Dingli, D., Zeldenrust, S.R., Mikhael, J.R., Hall, R., Rajkumar, S.V., Reeder, C., Fonseca, R., Bergsagel, P.L., Stewart, A.K., Roy, V., Witzig, T.E., Lust, J.A., Russell, S.J., Gertz, M.A. & Lacy, M.Q. (2012) The activity of pomalidomide in patients with immunoglobulin light chain amyloidosis. Blood, 119, 5397-5404.
31. Ehrnhoefer, D.E., Bieschke, J., Boeddrich, A., Herbst, M., Masino, L., Lurz, R., Engemann, S., Pastore, A. & Wanker, E.E. (2008) EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nature Structural & Molecular Biology, 15, 558-566.
32. Enrico, O., Gabriele, B., Nadia, C., Sara, G., Daniele, V., Giulia, C., Antonio, S. & Mario, P. (2007) Unexpected cardiotoxicity in haematological bortezomib treated patients. British Journal of Haematology, 138, 396-397.
33. Ferreira, N., Saraiva, M.J. & Almeida, M.R. (2011) Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation. FEBS Letters, 585, 2424-2430.
34. Ferreira, N., Saraiva, M.J. & Almeida, M.R. (2012) Natural polyphenols as modulators of TTR amyloidogenesis: in vitro and in vivo evidences towards therapy. Amyloid, 19(Suppl. 1), 39-42.
35. Gertz, M.A. (2010) I don't know how to treat amyloidosis. Blood, 116, 507-508.
36. Gertz, M., Lacy, M., Dispenzieri, A., Ansell, S., Elliott, M., Gastineau, D., Inwards, D., Micallef, I., Porrata, L., Tefferi, A. & Litzow, M. (2004) Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplantation, 34, 1025-1031.
37. Gertz, M., Lacy, M., Dispenzieri, A., Hayman, S., Kumar, S., Buadi, F., Leung, N. & Litzow, M. (2008) Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. Leukaemia & Lymphoma, 49, 36-41.
38. Gertz, M., Lacy, M., Dispenzieri, A., Kumar, S., Buadi, F., Dingli, D., Leung, N., Hogan, W. & Hayman, S. (2010) Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006. Bone Marrow Transplantation, 46, 970-975.
39. Gertz, M.A., Lacy, M.Q., Dispenzieri, A., Kumar, S.K., Dingli, D., Leung, N., Buadi, F.K. & Hayman, S.R. (2011) IgM amyloidosis: clinical features in therapeutic outcomes. Clinical Lymphoma, Myeloma & Leukemia, 11, 146-148.
40. Gertz, M.A., Lacy, M.Q., Dispenzieri, A., Kumar, S.K., Dingli, D., Leung, N., Hogan, W.J., Buadi, F.K. & Hayman, S.R. (2012) Refinement in patient selection can reduce the treatment-related mortality from stem cell transplantation in amyloidosis to <2%. XIIIth International Symposium on Amyloidosis, PC39. http://wencke4.housing.rug.nl/documenten/medici/Internationale_Conferenties/SY_Amyloidosis%202012/documents/ISAabstractbook2012.pdf.
41. Gibbs, S., De Cruz, M., Sattianayagam, P., Lachmann, H., Gillmore, J., Hawkins, P. & Wechalekar, A. (2009) Transient post chemotherapy rise in NT Pro-BNP in AL amyloidosis: implications for organ response assessment. ASH Annual Meeting Abstracts, Blood, 114, 712.
42. Gibbs, S.D.J., Venner, C.P., Foard, D., Rannigan, L., Pinney, J.H., Lane, T., Roussel, M., Banypersad, S., Whelan, C.J., Dungo, J., Lachmann, H.J., Gillmore, J.D., Wechalekar, A.D. & Hawkins, P.N. (2012) Subcutaneous bortezomib is effective and well tolerated for the treatment of systemic AL amyloidosis. XIIIth International Symposium on Amyloidosis, PC40. http://wencke4.housing.rug.nl/documenten/medici/Internationale_Conferenties/SY_Amyloidosis%202012/documents/ISAabstractbook2012.pdf.
43. Gillmore, J., Goodman, H., Lachmann, H., Offer, M., Wechalekar, A., Joshi, J., Pepys, M. & Hawkins, P. (2006) Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood, 107, 1227-1229.
44. Gillmore, J., Cocks, K., Gibbs, S., Sattianayagam, P., Lane, T., Lachmann, H., Schey, S., Cavenagh, J., Oakervee, H., Morgan, G., Mehta, A., Bourne, S., Skinner, E., Booth, G., Hawkins, P. & Wechalekar, A. (2009) Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Versus Melphalan Plus Dexamethasone (MD) for Newly-Diagnosed Systemic AL Amyloidosis - Results From the UK Amyloidosis Treatment Trial. ASH Annual Meeting Abstracts, Blood, 114, 1120.
45. Gillmore, J.D., Tennent, G.A., Hutchinson, W.L., Gallimore, J.R., Lachmann, H.J., Goodman, H.J., Offer, M., Millar, D.J., Petrie, A., Hawkins, P.N. & Pepys, M.B. (2010) Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. British Journal of Haematology, 148, 760-767.
46. Gillmore, J.D., Lane, T., Rannigan, L., Foard, D., Gibbs, S.D.J., Pinney, J.H., Venner, C.P., Banypersad, S., Lachmann, H.J., Wechalekar, A.D. & Hawkins, P.N. (2012) ALchemy - a large prospective 'real world' study of chemotherapy in AL amyloidosis. XIIIth International Symposium on Amyloidosis, OP39. http://wencke4.housing.rug.nl/documenten/medici/Internationale_Conferenties/SY_Amyloidosis%202012/documents/ISAabstractbook2012.pdf.
47. Hunstein, W. (2007) Epigallocathechin-3-gallate in AL amyloidosis: a new therapeutic option? Blood, 110, 2216.
48. Jaccard, A., Moreau, P., Leblond, V., Leleu, X., Benboubker, L., Hermine, O., Recher, C., Asli, B., Lioure, B., Royer, B., Jardin, F., Bridoux, F., Grosbois, B., Jaubert, J., Piette, J., Ronco, P., Quet, F., Cogne, M. & Fermand, J. (2007) High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. New England Journal of Medicine, 357, 1083-1093.
49. Jaccard, A., Leblond, V., Royer, B., Leleu, X., Delarue, R., Kolb, B., Deconinck, E., Stamatoullas, A., Coppo, P., Arnulf, B., Hermine, O., Moreau, P. & Fermand, J.P. (2010) Autologous stem cell transplantation (ASCT) versus oral melphalan and high-dose dexamethasone in patients with AL (primary) amyloidosis: long term follow-up of the french multicentric randomized trial. ASH Annual Meeting Abstracts, 116, 1344.
50. Jaccard, A., Comenzo, R.L., Wechalekar, A.D., Hawkins, P.N., Roussel, M., Morel, P., Macro, M., Longy-Boursier, M., Decaux, O., Bridoux, F. & Venner, C.P. (2012) Efficacy of bortezomib/cyclophosphamide/dexamethasone (VCD) chemotherapy in naïve patients with high risk cardiac light chain amyloidosis (Mayo Clinic stage III). XIIIth International Symposium on Amyloidosis. OP62. http://wencke4.housing.rug.nl/documenten/medici/Internationale_Conferenties/SY_Amyloidosis%202012/documents/ISAabstractbook2012.pdf.
51. Kastritis, E., Anagnostopoulos, A., Roussou, M., Toumanidis, S., Pamboukas, C., Migkou, M., Tassidou, A., Xilouri, I., Delibasi, S., Psimenou, E., Mellou, S., Terpos, E., Nanas, J. & Dimopoulos, M. (2007) Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica, 92, 1351-1358.
52. Kastritis, E., Wechalekar, A., Dimopoulos, M., Merlini, G., Hawkins, P., Perfetti, V., Gillmore, J. & Palladini, G. (2010) Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. Journal of Clinical Oncology, 28, 1031-1037.
53. Kastritis, E., Terpos, E., Roussou, M., Gavriatopoulou, M., Pamboukas, C., Boletis, I., Marinaki, S., Apostolou, T., Nikitas, N., Gkortzolidis, G., Michalis, E., Delimpasi, S. & Dimopoulos, M.A. (2012) A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. Blood, 119, 5384-5390.
54. Kristen, A.V., Lehrke, S., Buss, S., Mereles, D., Steen, H., Ehlermann, P., Hardt, S., Giannitsis, E., Schreiner, R., Haberkorn, U., Schnabel, P.A., Linke, R.P., Röcken, C., Wanker, E.E., Dengler, T.J., Altland, K. & Katus, H.A. (2012) Green tea halts progression of cardiac transthyretin amyloidosis: an observational report. Clinical Research in Cardiology, 101, 805-813.
55. Kumar, S., Gertz, M., Lacy, M., Dingli, D., Hayman, S.R., Buadi, F., Detweiler-Short, K., Zeldenrust, S., Leung, N., Greipp, P.R., Lust, J., Russell, S., Kyle, R., Rajkumar, V. & Dispenzieri, A. (2011) Recent improvements in survival in light chain amyloidosis and the importance of an early mortality risk score. ASH Annual Meeting Abstracts, 116, 1892.
56. Kumar, S., Dispenzieri, A., Lacy, M.Q., Hayman, S.R., Buadi, F.K., Colby, C., Laumann, K., Zeldenrust, S.R., Leung, N., Dingli, D., Greipp, P.R., Lust, J.A., Russell, S.J., Kyle, R.A., Rajkumar, S.V. & Gertz, M.A. (2012a) Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. Journal of Clinical Oncology, 30, 989-995.
57. Kumar, S.K., Hayman, S.R., Buadi, F.K., Roy, V., Lacy, M.Q., Gertz, M.A., Allred, J., Laumann, K.M., Bergsagel, L.P., Dingli, D., Mikhael, J.R., Reeder, C.B., Stewart, A.K., Zeldenrust, S.R., Greipp, P.R., Lust, J.A., Fonseca, R., Russell, S.J., Rajkumar, S.V. & Dispenzieri, A. (2012b) Lenalidomide, cyclophosphamide and dexamethasone (CRd) for light chain amyloidosis: long term results from a phase 2 trial. Blood, 11, 4860-4867.
58. Kyle, R., Gertz, M., Greipp, P., Witzig, T., Lust, J., Lacy, M. & Therneau, T. (1997) A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. New England Journal of Medicine, 336, 1202-1207.
59. Kyle, R.A., Therneau, T.M., Rajkumar, S.V., Offord, J.R., Larson, D.R., Plevak, M.F. & Melton, L.J. 3rd (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. New England Journal of Medicine, 346, 564-569.
60. Kyle, R.A., Therneau, T.M., Rajkumar, S.V., Larson, D.R., Plevak, M.F. & Melton, L.J. (2004) Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. Mayo Clinic Proceedings, 79, 859-866.
61. Lachmann, H., Booth, D., Booth, S., Bybee, A., Gilbertson, J., Gillmore, J., Pepys, M. & Hawkins, P. (2002) Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. New England Journal of Medicine, 346, 1786-1791.
62. Lacy, M.Q., Dispenzieri, A., Hayman, S.R., Kumar, S., Kyle, R.A., Rajkumar, S.V., Edwards, B.S., Rodeheffer, R.J., Frantz, R.P., Kushwaha, S.S., Clavell, A.L., Dearani, J.A., Sundt, T.M., Daly, R.C., McGregor, C.G., Gastineau, D.A., Litzow, M.R. & Gertz, M.A. (2008) Autologous stem cell transplant after heart transplant for light chain (AL) amyloid cardiomyopathy. Journal of Heart and Lung Transplantation, 27, 823-829.
63. Lacy, M.Q., Allred, J.B., Gertz, M.A., Hayman, S.R., Short, K.D., Buadi, F., Dispenzieri, A., Kumar, S., Greipp, P.R., Lust, J.A., Russell, S.J., Dingli, D., Zeldenrust, S., Fonseca, R., Bergsagel, P.L., Roy, V., Stewart, A.K., Laumann, K., Mandrekar, S.J., Reeder, C., Rajkumar, S.V. & Mikhael, J.R. (2011) Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood, 118, 2970-2975.
64. Lamm, W., Willenbacher, W., Lang, A., Zojer, N., Muldur, E., Ludwig, H., Schauer-Stalzer, B., Zielinski, C.C. & Drach, J. (2011) Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis. Annals of Hematology, 90, 201-206.
65. Landau, H., Hassoun, H., Bello, C., Hoover, E., Jia, X., Riedel, E.R., Nimer, S.D. & Comenzo, R.L. (2010) Adjuvant bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis. Amyloid, 17(Suppl. 1), 80.
66. Landau, H., Hassoun, H., Rosenzweig, M.A., Maurer, M., Liu, J., Flombaum, C., Bello, C., Hoover, E., Riedel, E., Giralt, S. & Comenzo, R.L. (2012) Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light chain amyloidosis. Leukemia, In press. [Epub ahead of print] doi: 10.1038/leu.2012.274.
67. Lavatelli, F. & Vrana, J.A. (2011) Proteomic typing of amyloid deposits in systemic amyloidoses. Amyloid, 18, 177-182.
68. Lavatelli, F., Perlman, D., Spencer, B., Prokaeva, T., McComb, M., Théberge, R., Connors, L., Bellotti, V., Seldin, D., Merlini, G., Skinner, M. & Costello, C. (2008) Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. Molecular and Cellular Proteomics, 7, 1570-1583.
69. Lavatelli, F., Valentini, V., Palladini, G., Verga, L., Russo, P., Foli, A., Obici, L., Sarais, G., Perfetti, V., Casarini, S. & Merlini, G. (2011) Mass spectrometry-based proteomics as a diagnostic tool when immunoelectron microscopy fails in typing amyloid deposits. Amyloid, 18(Suppl. 1), 59-61.
70. Lebovic, D., Hoffman, J., Levine, B.M., Hassoun, H., Landau, H., Goldsmith, Y., Maurer, M.S., Steingart, R.M., Cohen, A.D. & Comenzo, R.L. (2008) Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. British Journal of Haematology, 143, 369-373.
71. Ludwig, H., Durie, B.G., McCarthy, P., Palumbo, A., San Miguel, J., Barlogie, B., Morgan, G., Sonneveld, P., Spencer, A., Andersen, K.C., Facon, T., Stewart, K.A., Einsele, H., Mateos, M.V., Wijermans, P., Waage, A., Beksac, M., Richardson, P.G., Hulin, C., Niesvizky, R., Lokhorst, H., Landgren, O., Bergsagel, P.L., Orlowski, R., Hinke, A., Cavo, M. & Attal, M. (2012) IMWG consensus on maintenance therapy in multiple myeloma. Blood, 119, 3003-3015.
72. Madan, S., Dispenzieri, A., Lacy, M.Q., Buadi, F., Hayman, S.R., Zeldenrust, S.R., Rajkumar, S.V., Gertz, M.A. & Kumar, S.K. (2010a) Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma. Mayo Clinic Proceedings, 85, 232-238.
73. Madan, S., Kumar, S., Lacy, M., Dispenzieri, A., Buadi, F., Hayman, S.R., Dingli, D., Rajkumar, S.V. & Gertz, M. (2010b) Pre-stem cell transplant induction therapy does not affect post-transplant survival in light chain (AL) amyloidosis. ASH Annual Meeting Abstracts, 116, 370.
74. Madan, S., Kumar, S.K., Dispenzieri, A., Lacy, M.Q., Hayman, S.R., Buadi, F.K., Dingli, D., Rajkumar, S.V., Hogan, W.J., Leung, N., Grogan, M. & Gertz, M.A. (2012) High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. Blood, 119, 1117-1122.
75. Maramattom, L.V., Mazie Froedtert, W., Sue Froedtert Cancer, F., Singh, V., Cornell, R.F., Randhawa, J.K., Thomas, M., Saad, A.A., Palmer, J. & Hari, P. (2011) Bortezomib based therapy for newly diagnosed patients with advanced multisystem light chain amyloidosis (AL). Blood (ASH Annual Meeting Abstracts), 118, 1880.
76. Maurer, M., Raina, A., Hesdorffer, C., Bijou, R., Colombo, P., Deng, M., Drusin, R., Haythe, J., Horn, E., Lee, S., Marboe, C., Naka, Y., Schulman, L., Scully, B., Shapiro, P., Prager, K., Radhakrishnan, J., Restaino, S. & Mancini, D. (2007) Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure. Transplantation, 83, 539-545.
77. Mereles, D., Buss, S.J., Hardt, S.E., Hunstein, W. & Katus, H.A. (2010) Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis. Clinical Research in Cardiology, 99, 483-490.
78. Merlini, G. (2012) CyBorD: stellar response rates in AL amyloidosis. Blood, 119, 4343-4345.
79. Merlini, G. & Bellotti, V. (2003) Molecular mechanisms of amyloidosis. New England Journal of Medicine, 349, 583-596.
80. Merlini, G. & Stone, M. (2006) Dangerous small B-cell clones. Blood, 108, 2520-2530.
81. Merlini, G. & Westermark, P. (2004) The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies. Journal of Internal Medicine, 255, 159-178.
82. Merlini, G., Seldin, D.C. & Gertz, M.A. (2012) Amyloidosis: pathogenesis and new therapeutic options. Journal of Clinical Oncology, 29, 1924-1933.
83. Mikhael, J.R., Schuster, S.R., Jimenez-Zepeda, V.H., Bello, N., Spong, J., Reeder, C.B., Stewart, A.K., Bergsagel, P.L. & Fonseca, R. (2012) Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood, 119, 4391-4394.
84. Milani, P., Palladini, G., Foli, A., Obici, L., Lavatelli, F., Nuvolone, M., Perlini, S. & Merlini, G. (2012) Salvage therapy with bendamustine and prednisone (BeP) in AL amyloidosis: a pilot study. XIIIth International Symposium on Amyloidosis, OP63. http://wencke4.housing.rug.nl/documenten/medici/Internationale_Conferenties/SY_Amyloidosis%202012/documents/ISAabstractbook2012.pdf.
85. Mitsiades, C.S., Davies, F.E., Laubach, J.P., Joshua, D., San Miguel, J., Anderson, K.C. & Richardson, P.G. (2011) Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. Journal of Clinical Oncology, 29, 1916-1923.
86. Mollee, P., Tiley, C., Cunningham, I., Moore, J., Prince, H.M., Cannell, P., Gibbons, S., Tate, J., Paul, S., Mar Fan, H. & Gill, D.S. (2012) A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis. British Journal of Haematology, 157, 766-769.
87. Moreau, P. (1999) Autologous stem cell transplantation for AL amyloidosis: a standard therapy? Leukemia, 13, 1929-1931.
88. Moreau, P., Jaccard, A., Benboubker, L., Royer, B., Leleu, X., Bridoux, F., Salles, G., Leblond, V., Roussel, M., Alakl, M., Hermine, O., Planche, L., Harousseau, J. & Fermand, J. (2010) Lenalidomide in combination with melphalan and dexamethasone in patients with newly-diagnosed AL amyloidosis: a multicenter phase 1/2 dose escalation study. Blood, 116, 4777-4782.
89. Moreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M., Rekhtman, G., Masliak, Z., Robak, T., Shubina, A., Arnulf, B., Kropff, M., Cavet, J., Esseltine, D.L., Feng, H., Girgis, S., van de Velde, H., Deraedt, W. & Harousseau, J.L. (2011) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. The Lancet Oncology, 12, 431-440.
90. Obici, L., Perfetti, V., Palladini, G., Moratti, R. & Merlini, G. (2005) Clinical aspects of systemic amyloid diseases. Biochimica et Biophysica Acta, 1753, 11-22.
91. Oliva, L., Pengo, N., Palladini, G., Cascio, P., Pasqualetto, E., Merlini, G., Sitia, R. & Cenci, S. (2010) Proteasome activity and stress in light chain amyloidosis. Amyloid, 17, 99.
92. Oliva, L., Cerruti, F., Palladini, G., Orfanelli, U., Pengo, N., Cascio, P., Rognoni, P., Sitia, R., Merlini, G. & Cenci, S. (2012) Investigating vulnerability to proteasome inhibition in primary light chain amyloidosis. XIIIth International Symposium on Amyloidosis, OP10. http://wencke4.housing.rug.nl/documenten/medici/Internationale_Conferenties/SY_Amyloidosis%202012/documents/ISAabstractbook2012.pdf.
93. Palladini, G. & Merlini, G. (2011a) Uniform risk-stratification and response criteria are paving the way to evidence-based treatment of AL amyloidosis. Oncology (Williston Park), 25, 633, 637-638.
94. Palladini, G. & Merlini, G. (2011b) Transplantation vs. conventional-dose therapy for amyloidosis. Current Opinion in Oncology, 23, 214-220.
95. Palladini, G., Campana, C., Klersy, C., Balduini, A., Vadacca, G., Perfetti, V., Perlini, S., Obici, L., Ascari, E., d'Eril, G., Moratti, R. & Merlini, G. (2003) Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation, 107, 2440-2445.
96. Palladini, G., Perfetti, V., Obici, L., Caccialanza, R., Semino, A., Adami, F., Cavallero, G., Rustichelli, R., Virga, G. & Merlini, G. (2004) Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood, 103, 2936-2938.
97. Palladini, G., Perfetti, V., Perlini, S., Obici, L., Lavatelli, F., Caccialanza, R., Invernizzi, R., Comotti, B. & Merlini, G. (2005) The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood, 105, 2949-2951.
98. Palladini, G., Russo, P., Nuvolone, M., Lavatelli, F., Perfetti, V., Obici, L. & Merlini, G. (2007) Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood, 110, 787-788.
99. Palladini, G., Russo, P., Lavatelli, F., Nuvolone, M., Albertini, R., Bosoni, T., Perfetti, V., Obici, L., Perlini, S., Moratti, R. & Merlini, G. (2009a) Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Annals of Hematology, 88, 347-350.
100. Palladini, G., Russo, P., Bragotti, L., Foli, A., Musca, F., Lavateili, F., Perfetti, V., Obici, L., Perlini, S. & Merlini, G. (2009b) A phase II trial of cyclophosphamide, lenalidomide and dexamethasone (CLD) in previously treated patients with AL amyloidosis. ASH Annual Meeting Abstracts, Blood, 114, 1117-1118.
101. Palladini, G., Barassi, A., Klersy, C., Pacciolla, R., Milani, P., Sarais, G., Perlini, S., Albertini, R., Russo, P., Foli, A., Bragotti, L.Z., Obici, L., Moratti, R., d'Eril, G.V.M. & Merlini, G. (2010a) The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood, 116, 3426-3430.
102. Palladini, G., Dispenzieri, A., Gertz, M.A.A., Wechalekar, A., Hawkins, P.N., Schonland, S.O., Hegenbart, U., Comenzo, R.L., Kastritis, E., Dimopoulos, M.A., Jaccard, A., Klersy, C. & Merlini, G. (2010b) Validation of the criteria of response to treatment in AL amyloidosis. Blood, 116, 586-587.
103. Palladini, G., Foli, A., Milani, P., Russo, P., Zenone Bragotti, L., Perlini, S., Lavatelli, F., Obici, L., Perfetti, V. & Merlini, G. (2010c) Oral melphalan and dexamethasone for AL amyloidosis: efficacy, prognostic factors and response criteria. Amyloid, 17, 81-82.
104. Palladini, G., Milani, P., Foli, A., Russo, P., Lavatelli, F., Obici, L. & Merlini, G. (2011a) Treatment of AL amyloidosis with bortezomib combined with alkylating agents: results from a prospective series of unselected patients. Blood (ASH Annual Meeting Abstracts), 118, 3977.
105. Palladini, G., Foli, A., Russo, P., Milani, P., Obici, L., Lavatelli, F. & Merlini, G. (2011b) Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone. Clinical Lymphoma, Myeloma & Leukemia, 11, 143-145.
106. Palladini, G., Russo, P., Foli, A., Milani, P., Lavatelli, F., Obici, L., Nuvolone, M., Brugnatelli, S., Invernizzi, R. & Merlini, G. (2012a) Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide. Annals of Hematology, 91, 89-92.
107. Palladini, G., Dispenzieri, A., Gertz, M.A., Kumar, S., Wechalekar, A., Hawkins, P.N., Schönland, S., Hegenbart, U., Comenzo, R., Kastritis, E., Dimopoulos, M.A., Jaccard, A., Klersy, C. & Merlini, G. (2012b) New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. Journal of Clinical Oncology, [Epub ahead of print].
108. Palladini, G., Russo, P., Milani, P., Foli, A., Lavatelli, F., Nuvolone, M., Perlini, S. & Merlini, G. (2012c) A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. Haematologica, In press. [Epub ahead of print] doi: 10.3324/haematol.2012.073593.
109. Palladini, G., Foli, A., Milani, P., Obici, L., Lavatelli, F., Nuvolone, M., Perlini, S. & Merlini, G. (2012d) Melphalan and dexamethasone (MDex) vs. bortezomib, melphalan and dexamethasone (BMDex) in AL amyloidosis: a matched case-control study. XIIIth International Symposium on Amyloidosis, PC50. http://wencke4.housing.rug.nl/documenten/medici/Internationale_Conferenties/SY_Amyloidosis%202012/documents/ISAabstractbook2012.pdf.
110. Palumbo, A. & Anderson, K. (2011) Multiple myeloma. New England Journal of Medicine, 364, 1046-1060.
111. Patel, J., Sloan, J.M., Shelton, A.C., Finn, K.T. & Sanchorawala, V. (2011) Melphalan, lenalidomide and dexamethasone combination therapy in patients with AL amyloidosis. Blood (ASH Annual Meeting Abstracts), 118, 2924.
112. Pepys, M.B., Herbert, J., Hutchinson, W.L., Tennent, G.A., Lachmann, H.J., Gallimore, J.R., Lovat, L.B., Bartfai, T., Alanine, A., Hertel, C., Hoffmann, T., Jakob-Roetne, R., Norcross, R.D., Kemp, J.A., Yamamura, K., Suzuki, M., Taylor, G.W., Murray, S., Thompson, D., Purvis, A., Kolstoe, S., Wood, S.P. & Hawkins, P.N. (2002) Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature, 417, 254-259.
113. Petruzziello, F., Zeppa, P., Catalano, L., Cozzolino, I., Gargiulo, G., Musto, P., D'Auria, F., Liso, V., Rizzi, R., Caruso, N., Califano, C., Piro, E., Musso, M., Bonanno, V., Pia Falcone, A., Tafuto, S., Di Raimondo, F., De Laurentiis, M., Pane, F., Palombini, L. & Rotoli, B. (2010) Amyloid in bone marrow smears of patients affected by multiple myeloma. Annals of Hematology, 89, 469-474.
114. Phipps, J.E., Kestler, D.P., Foster, J.S., Kennel, S.J., Donnell, R., Weiss, D.T., Solomon, A. & Wall, J.S. (2010) Inhibition of pathologic immunoglobulin-free light chain production by small interfering RNA molecules. Experimental Hematology, 38, 1006-1013.
115. Quillen, K., Seldin, D.C., Finn, K.T. & Sanchorawala, V. (2011) A second course of high-dose melphalan and auto-SCT for the treatment of relapsed AL amyloidosis. Bone Marrow Transplantation, 46, 976-980.
116. Rajkumar, S.V., Gertz, M.A. & Kyle, R.A. (1998a) Primary systemic amyloidosis with delayed progression to multiple myeloma. Cancer, 82, 1501-1505.
117. Rajkumar, S.V., Gertz, M.A. & Kyle, R.A. (1998b) Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy. American Journal of Medicine, 104, 232-237.
118. Reece, D.E., Hegenbart, U., Sanchorawala, V., Merlini, G., Palladini, G., Blade, J., Fermand, J.P., Hassoun, H., Heffner, L., Vescio, R.A., Liu, K., Enny, C., Esseltine, D.L., van de Velde, H., Cakana, A. & Comenzo, R.L. (2011) Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood, 118, 865-873.
119. Rezai-Zadeh, K., Shytle, D., Sun, N., Mori, T., Hou, H., Jeanniton, D., Ehrhart, J., Townsend, K., Zeng, J., Morgan, D., Hardy, J., Town, T. & Tan, J. (2005) Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. Journal of Neuroscience, 25, 8807-8814.
120. Sack, F., Kristen, A., Goldschmidt, H., Schnabel, P., Dengler, T., Koch, A. & Karck, M. (2008) Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis. European Journal of Cardio-Thoracic Surgery, 33, 257-262.
121. Sanchorawala, V., Skinner, M., Quillen, K., Finn, K., Doros, G. & Seldin, D. (2007a) Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood, 110, 3561-3563.
122. Sanchorawala, V., Wright, D., Rosenzweig, M., Finn, K., Fennessey, S., Zeldis, J., Skinner, M. & Seldin, D. (2007b) Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood, 109, 492-496.
123. Sanchorawala, V., Finn, K.T., Fennessey, S., Shelton, A., Doros, G., Zeldis, J.B. & Seldin, D.C. (2010a) Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis. Blood, 116, 1990-1991.
124. Sanchorawala, V., Finn, K.T., Fennessey, S., Shelton, A.C., Zeldis, J.B. & Seldin, D.C. (2010b) Lenalidomide treatment in patients with AL amyloidosis associated end-stage renal disease and dialysis. Blood (ASH Annual Meeting Abstracts), 116, 3022.
125. Sanchorawala, V., Hoering, A., Seldin, D.C., Finn, K.T., Fennessey, S.A., Mattar, B.I., Safah, H.F., Holmberg, L., Dean, R.M., Orlowski, R.Z. & Barlogie, B. (2011) Modified high-dose melphalan and autologous stem cell transplantation (mHDM/SCT) in the treatment of AL amyloidosis (AL) and/or high-risk myeloma (hM): analysis of SWOG trial S0115. Blood (ASH Annual Meeting Abstracts), 118, 2004.
126. Sanchorawala, V., Alam, M., Shelton, A., Brauneis, D., Andrea, N.T., Sloan, J.M. & Seldin, D.C. (2012a) Treatment of AL amyloidosis with 2 cycles of induction therapy with bortezomib and dexamethasone followed by bortezomib-high dose melphalan conditioning and autologous stem cell transplantation. XIIIth International Symposium on Amyloidosis. PC53. http://wencke4.housing.rug.nl/documenten/medici/Internationale_Conferenties/SY_Amyloidosis%202012/documents/ISAabstractbook2012.pdf.
127. Sanchorawala, V., Zonder, J.A., Comenzo, R.L., Schönland, S.O., Berg, D., Liu, G., Gupta, N., Hui, A. & Merlini, G. (2012b) Phase I study of MLN9708, a novel, investigational oral proteasome inhibitor, in patients with relapsed or refractory light-chain amyloidosis (AL). XIIIth International Symposium on Amyloidosis, PC54. http://wencke4.housing.rug.nl/documenten/medici/Internationale_Conferenties/SY_Amyloidosis%202012/documents/ISAabstractbook2012.pdf.
128. Satoskar, A., Burdge, K., Cowden, D., Nadasdy, G., Hebert, L. & Nadasdy, T. (2007) Typing of amyloidosis in renal biopsies: diagnostic pitfalls. Archives of Pathology and Laboratory Medicine, 131, 917-922.
129. Sattianayagam, P.T., Gibbs, S.D., Pinney, J.H., Wechalekar, A.D., Lachmann, H.J., Whelan, C.J., Gilbertson, J.A., Hawkins, P.N. & Gillmore, J.D. (2010) Solid organ transplantation in AL amyloidosis. American Journal of Transplantation, 10, 2124-2131.
130. Schonland, S.O., Bochtler, T., Perz, J., Hansberg, M., Mangatter, A., Ho, A.D., Goldschmidt, H. & Hegenbart, U. (2010a) Results of two consecutive phase II trials of patients with systemic AL amyloidosis treated with high-dose melphalan after induction and mobilization chemotherapy. Amyloid, 17, 80-81.
131. Schonland, S.O., Bochtler, T., Ho, A.D. & Hegenbart, U. (2010b) Efficacy and toxicity of dose-reduced bortezomib/dexamethasone chemotherapy in patients with high risk cardiac light chain amyloidosis (Mayo Clinic stage III). Blood (ASH Annual Meeting Abstracts), 116, 1960.
132. Schönland, S., Lokhorst, H., Buzyn, A., Leblond, V., Hegenbart, U., Bandini, G., Campbell, A., Carreras, E., Ferrant, A., Grommisch, L., Jacobs, P., Kröger, N., La Nasa, G., Russell, N., Zachee, P., Goldschmidt, H., Iacobelli, S., Niederwieser, D. & Gahrton, G. (2006) Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation. Blood, 107, 2578-2584.
133. Schönland, S.O., Hegenbart, U., Bochtler, T., Mangatter, A., Hansberg, M., Ho, A.D., Lohse, P. & Röcken, C. (2012) Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood, 119, 488-493.
134. Seldin, D., Choufani, E., Dember, L., Wiesman, J., Berk, J., Falk, R., O'Hara, C., Fennessey, S., Finn, K., Wright, D., Skinner, M. & Sanchorawala, V. (2003) Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clinical Lymphoma, 3, 241-246.
135. Siragusa, S., Morice, W., Gertz, M.A., Kyle, R.A., Greipp, P.R., Lust, J.A., Witzig, T.E., Lacy, M.Q., Zeldenrust, S.R., Rajkumar, S.V., Russell, S.J., Hayman, S.R., Buadi, F., Kumar, S.K., Dingli, D. & Dispenzieri, A. (2011) Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature. Annals of Hematology, 90, 101-106.
136. Sitia, R., Palladini, G. & Merlini, G. (2007) Bortezomib in the treatment of AL amyloidosis: targeted therapy? Haematologica-The Hematology Journal, 92, 1302-1307.
137. Skinner, M., Anderson, J., Simms, R., Falk, R., Wang, M., Libbey, C., Jones, L. & Cohen, A. (1996) Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. American Journal of Medicine, 100, 290-298.
138. Skinner, M., Sanchorawala, V., Seldin, D., Dember, L., Falk, R., Berk, J., Anderson, J., O'Hara, C., Finn, K., Libbey, C., Wiesman, J., Quillen, K., Swan, N. & Wright, D. (2004) High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Annals of Internal Medicine, 140, 85-93.
139. Specter, R., Sanchorawala, V., Seldin, D., Shelton, A., Fennessey, S., Finn, K., Zeldis, J. & Dember, L. (2011) Kidney dysfunction during lenalidomide treatment for AL amyloidosis. Nephrology, Dialysis, Transplantation, 26, 881-886.
140. Tapan, U., Seldin, D.C., Finn, K.T., Fennessey, S., Shelton, A., Zeldis, J.B. & Sanchorawala, V. (2010) Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis. Blood, 116, 5071-5072.
141. Tovar, N., Cibeira, T., Rosiñol, L., Fernández de Larrea, C., Escoda, L., Rovira, M. & Bladé, J. (2012) Bortezomib/dexamethasone followed by autologous stem cell transplantation as front line treatment for light chain deposition disease. XIIIth International Symposium on Amyloidosis PC64. http://wencke4.housing.rug.nl/documenten/medici/Internationale_Conferenties/SY_Amyloidosis%202012/documents/ISAabstractbook2012.pdf.
142. Vela-Ojeda, J., Garcia-Ruiz Esparza, M.A., Padilla-Gonzalez, Y., Sanchez-Cortes, E., Garcia-Chavez, J., Montiel-Cervantes, L., Reyes-Maldonado, E., Majluf-Cruz, A. & Mayani, H. (2009) Multiple myeloma-associated amyloidosis is an independent high-risk prognostic factor. Annals of Hematology, 88, 59-66.
143. Venner, C.P., Gillmore, J.D., Lane, T., Foard, D., Rannigan, L., Gibbs, S.D.J., Pinney, J., Whelan, C., Lachmann, H., Hawkins, P.N. & Wechalekar, A. (2011) Complete and very good partial responses are attainable endpoints in elderly patients (>75 years) with AL amyloidosis and are associated with improved overall survival. Blood (ASH Annual Meeting Abstracts), 118, 3975.
144. Venner, C.P., Lane, T., Foard, D., Rannigan, L., Gibbs, S.D., Pinney, J.H., Whelan, C.J., Lachmann, H.J., Gillmore, J.D., Hawkins, P.N. & Wechalekar, A.D. (2012) Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood, 119, 4387-4390.
145. Verga, L., Corona, S., Obici, L., Morbini, P., Lavatelli, F., Donadei, S., Sarais, G., Roggeri, L., Foli, A., Russo, P., Bragotti, L.Z., Paulli, M., Minoli, L., Magrini, U. & Merlini, G. (2010) Diagnostic performance of immuno-electron microscopy of abdominal fat in systemic amyloidoses. Amyloid-Journal of Protein Folding Disorders, 17, 59-60.
146. Vrana, J., Gamez, J., Madden, B., Theis, J., Bergen, H.R. & Dogan, A. (2009) Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood, 114, 4957-4959.
147. Wechalekar, A., Goodman, H., Lachmann, H., Offer, M., Hawkins, P. & Gillmore, J. (2007) Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood, 109, 457-464.
148. Wechalekar, A., Merlini, G., Gillmore, J.D., Russo, P., Lachmann, H.J., Obici, L., Hawkins, P.N. & Palladini, G. (2008a) Role of NT-ProBNP to assess the adequacy of treatment response in AL amyloidosis. Blood, 112, 596-597.
149. Wechalekar, A.D., Lachmann, H.J., Goodman, H.J., Bradwell, A., Hawkins, P.N. & Gillmore, J.D. (2008b) AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. Blood, 112, 4009-4016.
150. Wechalekar, A., Schonland, S.O., Kastritis, E., Hawkins, P.N., Dimopoulos, M.A., Russo, P., Lane, T., Foli, A., Foard, D., Milani, P., Rannigan, L., Hegenbart, U., Gillmore, J.D., Merlini, G. & Palladini, G. (2011) European collaborative study of treatment outcomes in 347 patients with systemic AL amyloidosis with mayo stage III disease. Blood (ASH Annual Meeting Abstracts), 118, 995.
151. Wechalekar, A.D., Gillmore, J.D., Foard, D., Rannigan, L., Lane, T., Pinney, J.H., Gibbs, S.D.J., Venner, C.P., Banypersad, S., Whelan, C.J., Lachmann, H.J. & Hawkins, P.N. (2012) Evaluation of an early switch to second line chemotherapy in AL amyloidosis among patients who fail to achieve a very good partial response to frontline treatment. XIIIth International Symposium on Amyloidosis. OP39. http://wencke4.housing.rug.nl/documenten/medici/Internationale_Conferenties/SY_Amyloidosis%202012/documents/ISAabstractbook2012.pdf.
152. Zonder, J., Sanchorawala, V., Snyder, R., Matous, J., Terebelo, H., Janakiraman, N., Mapara, M., Lalo, S., Tageja, N., Webb, C., Monsma, D., Sellers, C., Abrams, J. & Gasparetto, C. (2009) Melphalan and dexamethasone plus bortezomib induces hematologic and organ responses in AL-amyloidosis with tolerable neurotoxicity. ASH Annual Meeting Abstracts, Blood, 114, 310-311.